Asymchem Awarded ‘Project Excellence Award’ by Mersana

Antibody-Drug Conjugates (ADCs) have become a popular direction for global antibody drug R&D with their advantages in the field of oncology therapeutics. As a leading global CDMO company, Asymchem sought the opportunity to build a one-stop CDMO service platform for ADCs. Because of the diligence in this area, Asymchem was recently awarded the “Project Excellence Award” by Mersana Therapeutics for the outstanding service.

In recent years, ADC technology has continued to mature as the drug treatment window continues to widen, and domestic and international R&D enthusiasm has been unprecedentedly high. In 2020, the industry deals completed around ADC drugs reached nearly $40 billion. According to PR Newswire, the market size of ADC drugs will reach $10 billion in 2025, and is even expected to challenge the next $100 billion market.

As a leading CDMO company in new drug development, Asymchem has gradually established and optimized our ADC drug service platform over the past 10 years. Relying on the R&D center, analytical testing center and pilot production base, it can provide one-stop CDMO R&D and production services including antibody production, antibody modification, toxin-conjugate production and antibody-toxin coupling for the development of ADC drugs, promoting the accelerated arrival of the ADC drug wave.

R&D and production capacity in the Biologics Department of Asymchem can provide technical support and quality assurance for the development of ADC drugs. Currently, the three R&D centers have a total of more than 180 senior scientists, which will support the R&D of ADC projects for domestic and international customers.

All of Asymchem’s manufacturing sites follow international uniform quality standards and have successfully passed dozens of audits, including FDA, NMPA and TGA. To date, Asymchem’s Macromolecule Division has provided CMC services to more than 40 clients at different stages of projects, covering many major international pharmaceutical companies and Biotech companies active in related fields.

Massachusetts-based Mersana Therapeutics is a Biotech company. Recently, in the collaboration between Asymchem and Mersana Therapeutics, Asymchem’s chemical macromolecule team successfully solved the key process difficulties and optimized the process flow, completing the expected one-year validation project four months ahead of schedule. Mersana said, “We are impressed by and appreciate the dedication and great effort from all team members at Asymchem. This high quality work further demonstrates that Asymchem is a leader in the CDMO industry, and is a highlight of our successful business relationship.”